Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Comorbidity Index’s Role in Transplant Recipients
Biol Blood Marrow Transplant; ePub 2017 Jun 28; Veeraputhiran, et al
The hematopoietic cell transplant-comorbidity index (HCT-CI) can predict all-cause mortality in patients treated with a specific allogeneic HCT regimen, according to a retrospective analysis involving 287 individuals. Participants received allogeneic HCT with a regimen consisting of non-myeloablative total lymphoid irradiation and anti-thymocyte globulin. Investigators looked at the link between HCT-CI and both non-relapse and all-cause mortality. Among the results:
- 89 patients had reduced pulmonary function; 39 had prior history of malignancy; 38 had a psychiatric condition; and 31 had diabetes.
- Patients with higher HCT-CI score of 1-2 had a nearly 2-fold higher all-cause mortality risk; those with a score of ≥3 had an 85% higher risk.
- Patients with diabetes had a more than 2-fold higher risk of all-cause mortality.
- Those with prior solid tumors had a 75% higher risk of such.
Veeraputhiran M, Yang L, Sundaram V, et al. Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation. [Published online ahead of print June 28, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.06.005.